Literature DB >> 34043065

Dysphagia, trismus and speech impairment following radiation-based treatment for advanced stage oropharyngeal carcinoma: a one-year prospective evaluation.

Rebecca T Karsten1, Najiba Chargi2, Lisette van der Molen1,3, Rob J J H van Son1,3, Remco de Bree2, Abrahim Al-Mamgani4, Jan P de Boer5, Frans J M Hilgers1,3, Michiel W M van den Brekel6,7, Ludi E Smeele1,8, Martijn M Stuiver1.   

Abstract

OBJECTIVE: The objective was to assess swallowing, mouth opening and speech function during the first year after radiation-based treatment (RT(+)) after introduction of a dedicated preventive rehabilitation program for stage III-IV oropharyngeal carcinoma (OPC).
METHODS: Swallowing, mouth opening and speech function were collected before and at six- and twelve-month follow-up after RT(+) for OPC as part of ongoing prospective assessments by speech-language pathologists .
RESULTS: Objective and patient-perceived function deteriorated until 6 months and improved until 12 months after treatment, but did not return to baseline levels with 25%, 20% and 58% of the patients with objective dysphagia, trismus and speech problems, respectively. Feeding tube dependency and pneumonia prevalence was low.
CONCLUSION: Despite successful implementation, a substantial proportion of patients still experience functional limitations after RT(+) for OPC, suggesting room for improvement of the current rehabilitation program. Pretreatment sarcopenia seems associated with worse functional outcomes and might be a relevant new target for rehabilitation strategies.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Chemoradiotherapy; Dysphagia; Oropharyngeal carcinoma; Radiotherapy; Sarcopenia; Speech; Trismus

Mesh:

Year:  2021        PMID: 34043065     DOI: 10.1007/s00405-021-06870-x

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  38 in total

1.  Dysphagia and trismus after concomitant chemo-Intensity-Modulated Radiation Therapy (chemo-IMRT) in advanced head and neck cancer; dose-effect relationships for swallowing and mastication structures.

Authors:  Lisette van der Molen; Wilma D Heemsbergen; Rianne de Jong; Maya A van Rossum; Ludi E Smeele; Coen R N Rasch; Frans J M Hilgers
Journal:  Radiother Oncol       Date:  2013-03-26       Impact factor: 6.280

2.  Single-item discrimination of quality-of-life-altering dysphagia among 714 long-term oropharyngeal cancer survivors: Comparison of patient-reported outcome measures of swallowing.

Authors:  Stephen Grant; Mona Kamal; Abdallah S R Mohamed; Jhankruti Zaveri; Martha P Barrow; G Brandon Gunn; Stephen Y Lai; Jan S Lewin; David I Rosenthal; Xin Shelley Wang; Clifton D Fuller; Katherine A Hutcheson
Journal:  Cancer       Date:  2019-01-11       Impact factor: 6.860

Review 3.  Physiological changes to the swallowing mechanism following (chemo)radiotherapy for head and neck cancer: a systematic review.

Authors:  Laurelie R Wall; Elizabeth C Ward; Bena Cartmill; Anne J Hill
Journal:  Dysphagia       Date:  2013-12       Impact factor: 3.438

4.  Effects of radiotherapy with or without chemotherapy on tongue strength and swallowing in patients with oral cancer.

Authors:  Cathy Lazarus; Jeri A Logemann; Barbara Roa Pauloski; Alfred W Rademaker; Irene B Helenowski; Edward F Vonesh; Ellen Maccracken; Bharat B Mittal; Everett E Vokes; Daniel J Haraf
Journal:  Head Neck       Date:  2007-07       Impact factor: 3.147

5.  Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes.

Authors:  Klaudia U Hunter; Matthew Schipper; Felix Y Feng; Teresa Lyden; Mark Haxer; Carol-Anne Murdoch-Kinch; Benjamin Cornwall; Connie S Y Lee; Douglas B Chepeha; Avraham Eisbruch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-10-03       Impact factor: 7.038

6.  Swallowing outcomes in patients with oropharyngeal cancer undergoing organ-preservation treatment.

Authors:  Heather M Starmer; Donna Tippett; Kimberly Webster; Harry Quon; Bronwyn Jones; Sarah Hardy; Christine G Gourin
Journal:  Head Neck       Date:  2014-01-13       Impact factor: 3.147

7.  Late dysphagia after radiotherapy-based treatment of head and neck cancer.

Authors:  Katherine A Hutcheson; Jan S Lewin; Denise A Barringer; Asher Lisec; G Brandon Gunn; Michael W S Moore; F Christopher Holsinger
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860

8.  The surgical dilemma of 'functional inoperability' in oral and oropharyngeal cancer: current consensus on operability with regard to functional results.

Authors:  A Kreeft; I B Tan; M W M van den Brekel; F J Hilgers; A J M Balm
Journal:  Clin Otolaryngol       Date:  2009-04       Impact factor: 2.597

9.  Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers.

Authors:  Anil K Chaturvedi; William F Anderson; Joannie Lortet-Tieulent; Maria Paula Curado; Jacques Ferlay; Silvia Franceschi; Philip S Rosenberg; Freddie Bray; Maura L Gillison
Journal:  J Clin Oncol       Date:  2013-11-18       Impact factor: 44.544

10.  Prevalence and prediction of trismus in patients with head and neck cancer: A cross-sectional study.

Authors:  Sarah J van der Geer; Phillip V van Rijn; Jolanda I Kamstra; Johannes A Langendijk; Bernard F A M van der Laan; Jan L N Roodenburg; Pieter U Dijkstra
Journal:  Head Neck       Date:  2018-12-18       Impact factor: 3.147

View more
  2 in total

1.  Sentinel node biopsy or elective neck dissection in early oral cancer: a point of contention.

Authors:  Abhijeet Singh; Anand Subash; Piyush Sinha
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-10-08       Impact factor: 2.503

Review 2.  Measurement of Sarcopenia in Head and Neck Cancer Patients and Its Association With Frailty.

Authors:  Remco de Bree; Christiaan D A Meerkerk; Gyorgy B Halmos; Antti A Mäkitie; Akihiro Homma; Juan P Rodrigo; Fernando López; Robert P Takes; Jan B Vermorken; Alfio Ferlito
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.